Active surveillance for prostate cancer is a monitoring approach rather than immediate treatment. If you have localised, low-risk prostate cancer, your consultant may recommend tracking the cancer with regular tests instead of surgery or radiotherapy. You avoid treatment unless tests show the cancer is growing or your situation changes. This approach helps you skip the side effects of treatment that many men never need.
This guide explains how active surveillance works and whether it suits your situation. You’ll learn who qualifies for this approach, what the monitoring process involves, and how it differs from watchful waiting. We’ll cover the benefits and risks you need to weigh, the tests you can expect, and the key questions to ask your urologist. By the end, you’ll understand how to make an informed choice about active surveillance and know when treatment becomes necessary. Whether you’ve just been diagnosed or you’re considering your options after a second opinion, this information will help you decide with confidence.
Why active surveillance matters
Many prostate cancers never progress to cause symptoms or shorten your life. Research shows that localised prostate cancer often grows slowly, and in some cases, it doesn’t grow at all. You face a decision between treating a cancer that might never harm you and monitoring it carefully until treatment becomes necessary.
The case for monitoring instead of treating
Treatment brings real consequences that affect your daily life. Surgery and radiotherapy both cause side effects that can persist for years or become permanent. You might experience urinary incontinence, erectile dysfunction, or bowel problems after treatment. These side effects happen regardless of whether the cancer would have caused problems in the first place.
Studies tracking thousands of men show that active surveillance prostate cancer programmes deliver outcomes comparable to immediate treatment for appropriate candidates. The 10-year survival rates match those of men who chose surgery or radiotherapy straight away. You gain the same long-term protection whilst potentially avoiding years of treatment-related complications.
Active surveillance lets you maintain your quality of life whilst staying protected against cancer progression through regular monitoring.
What this approach preserves
Your physical function matters beyond cancer outcomes. Erectile function remains intact when you avoid prostate surgery or radiation. Urinary control stays normal without the risk of incontinence that treatment brings. These aspects of your health directly affect your relationships, work life, and daily comfort.
The monitoring programme catches changes early enough to treat effectively. Regular PSA tests, MRI scans, and consultations create a safety net that identifies cancer growth before it becomes dangerous. You switch to active treatment only if tests indicate progression, meaning you receive intervention at the right time rather than unnecessarily early.
This approach also gives you time. You can research treatment options thoroughly, understand potential side effects in detail, and prepare mentally for intervention if it becomes necessary. Some men never need treatment at all, whilst others benefit from having months or years to make informed decisions about their care.
How to decide on active surveillance
Your consultant considers specific factors when recommending active surveillance prostate cancer as an option. The decision depends on your cancer’s characteristics, your overall health, and your personal priorities. You need to understand each factor to make the right choice for your situation.
Your cancer characteristics matter most
Your Gleason score determines whether active surveillance suits you. Men with Gleason 3+3 cancer (low risk) make ideal candidates because this grade grows very slowly and rarely spreads. Some men with Gleason 3+4 cancer (intermediate risk with favourable features) also qualify, though this requires careful assessment. Your Cambridge Prognostic Group (CPG) provides another way to understand your risk. CPG 1 and CPG 2 cancers work well with active surveillance, whilst CPG 3 sometimes qualifies depending on other factors.
The stage of your cancer matters as much as the grade. Your cancer must remain contained within the prostate gland, which doctors call localised prostate cancer. MRI scans and biopsy results show whether cancer has spread beyond the prostate capsule. If imaging reveals cancer extension or lymph node involvement, active surveillance becomes unsuitable.
Your PSA level and PSA density (PSA divided by prostate volume) provide additional information. Lower PSA values suggest less aggressive disease. Your consultant examines all these test results together rather than relying on any single measurement.
Your overall health influences the decision
Active surveillance only works if you remain healthy enough for treatment should your cancer progress. Your fitness for surgery or radiotherapy matters because these options need to stay available. Men with serious heart conditions, lung disease, or other major health problems might not tolerate aggressive treatment later. Your consultant assesses whether you could safely undergo radical prostatectomy or radiotherapy in five or ten years’ time.
Your life expectancy plays a role in the decision. If you have a life expectancy of less than ten years due to other health conditions, watchful waiting might suit you better than active surveillance. Active surveillance assumes you’ll live long enough that cancer progression could affect you. Men in their 40s or 50s face different considerations than those in their 70s or 80s.
Active surveillance makes sense when you’re healthy enough for future treatment but healthy enough now to avoid it.
Your ability to attend regular appointments matters too. The monitoring programme requires commitment to PSA tests every three to six months, annual MRI scans, and possible repeat biopsies. You need reliable transport, the flexibility to attend appointments, and the organisational skills to track your schedule.
Your personal priorities shape the choice
Some men find the idea of living with untreated cancer deeply uncomfortable. Your psychological response to active surveillance affects whether it suits you. If constant worry about cancer progression would damage your mental health, immediate treatment might serve you better even if your cancer characteristics suggest surveillance would work.
Your tolerance for uncertainty influences the decision. Active surveillance means accepting that cancer exists in your body whilst trusting the monitoring programme to catch any concerning changes. Men who prefer definitive action often struggle with this approach. Those who value avoiding treatment side effects typically adapt well to regular monitoring.
Your work and lifestyle commitments matter. Treatment disrupts your schedule for weeks or months, whilst active surveillance requires just a few hours every few months. You might prefer surveillance if you’re still working, caring for family members, or pursuing activities that treatment would interrupt. Conversely, planned retirement or career changes might make treatment timing less critical for you.
What active surveillance involves
Active surveillance prostate cancer programmes follow a structured monitoring schedule that varies slightly between hospitals. You attend regular appointments and complete specific tests at defined intervals. The monitoring catches any cancer changes early whilst you continue your normal life between appointments. Your consultant creates an individual plan based on your cancer characteristics and hospital protocols.
Your monitoring schedule
Your first year on active surveillance involves the most frequent monitoring. You have a PSA blood test every three to four months, which means four tests spread across twelve months. Your consultant reviews each result at a telephone appointment or clinic visit. Around twelve months after diagnosis, you typically have an MRI scan and possibly a digital rectal examination (DRE). This first year establishes your baseline pattern and confirms the cancer remains stable.
From the second year onwards, monitoring becomes less intensive. You move to PSA tests every six months rather than quarterly. Annual appointments include a DRE where your consultant feels the prostate through the rectal wall to check for changes. MRI scans happen every one to two years depending on your hospital’s protocol and your specific situation. Some programmes offer remote monitoring between face-to-face appointments, where stable PSA results trigger an automatic letter rather than a consultation.
Regular monitoring creates a safety net that identifies concerning changes whilst you avoid treatment side effects.
The tests you’ll have
PSA blood tests measure prostate-specific antigen levels in your blood. You book these tests yourself at your GP surgery or hospital phlebotomy service one to two weeks before each scheduled appointment. Your PSA level naturally varies, so your consultant looks for trends rather than single results. A steady rise faster than expected might indicate cancer growth, though infections, recent ejaculation, or vigorous exercise also affect PSA temporarily.
MRI scans provide detailed images of your prostate without radiation. You lie in the scanner for about thirty to forty minutes whilst the machine takes pictures. The first MRI scan when you start active surveillance confirms cancer hasn’t spread beyond the prostate. Later scans compare against this baseline to spot any growth or new areas of concern. Your consultant orders additional MRI scans if your PSA results raise questions.
Digital rectal examinations take just minutes during your appointment. Your consultant inserts a gloved finger into your rectum to feel the prostate gland. A normal prostate feels soft and smooth, whilst cancer can create hard or lumpy areas. Many men find this examination less uncomfortable than they expected, and it provides valuable information your consultant can’t get from blood tests alone.
Prostate biopsies happen less frequently than other tests. You might not need another biopsy after your diagnostic one unless other test results suggest cancer changes. Transperineal biopsies (through the skin between testicles and back passage) carry lower infection risk than older trans-rectal methods. Your consultant discusses whether you need a repeat biopsy based on your PSA trends and MRI findings.
What happens at your appointments
Telephone consultations have become standard for routine follow-ups. Your consultant or specialist nurse reviews your latest PSA result and asks about any new symptoms. These calls typically last ten to fifteen minutes and save you a hospital journey. Face-to-face appointments happen when you need physical examination or when results need detailed discussion.
You receive appointment reminders by post, text message, or email depending on your hospital. Booking PSA tests remains your responsibility in most programmes, so keeping track of dates matters. Missing appointments or delaying tests creates gaps in your monitoring that could allow cancer changes to go undetected. Your consultant’s team provides contact details for any questions between scheduled appointments.
Some hospitals use patient portals where you access test results online. Your medical records track every PSA value, scan report, and consultation note to create a complete picture of your cancer’s behaviour over time. This information helps your consultant make evidence-based decisions about whether you can safely continue surveillance or need treatment.
Benefits and risks of active surveillance
Active surveillance prostate cancer programmes deliver clear benefits for men with low-risk disease, but they also carry specific risks you need to understand. Your decision depends on weighing these factors against your personal circumstances. The advantages often outweigh the risks for men with localised, slow-growing cancer, though every situation differs. Your consultant helps you evaluate both sides of the equation based on your test results and health status.
What you gain from active surveillance
You avoid treatment side effects that can permanently affect your quality of life. Surgery to remove the prostate causes erectile dysfunction in 30 to 70 per cent of men, depending on the surgical technique and your age. Urinary incontinence affects 5 to 20 per cent of men after surgery, requiring pads or further procedures. Radiotherapy brings different but equally troublesome effects, including bowel urgency, rectal bleeding, and bladder irritation that can persist for years. Active surveillance lets you skip these complications entirely whilst the cancer remains stable.
Your daily life continues without interruption. Treatment requires weeks of recovery from surgery or daily radiotherapy sessions for several weeks. You miss work, pause physical activities, and need help with basic tasks during recovery. Monitoring appointments take just hours every few months, leaving your routine largely unchanged. You maintain your independence, continue working, and keep up with hobbies and social commitments.
Active surveillance protects your quality of life whilst providing the same long-term survival outcomes as immediate treatment for appropriate candidates.
Financial and practical benefits matter too. Surgery costs range into thousands of pounds even in private care, whilst radiotherapy involves multiple appointments over weeks. Active surveillance involves simpler tests at lower cost. Travel and time commitments decrease significantly when you attend quarterly blood tests rather than daily treatment sessions.
The side effects you completely avoid
Erectile function remains normal without surgery or radiation damaging the nerves and blood vessels around your prostate. This matters for intimate relationships and personal wellbeing at any age. Treatment affects sexual function in ways that medications can only partially address. Urinary control stays intact when you avoid procedures that can weaken sphincter muscles. You don’t need pads, worry about leakage during exercise, or plan activities around bathroom access.
Bowel function remains unchanged on active surveillance. Radiotherapy can cause chronic diarrhoea and urgency that disrupts travel, work meetings, and social occasions. You might need medication to manage these symptoms long after treatment ends. Active surveillance avoids all these complications whilst you remain healthy and the cancer stays contained.
Understanding the risks you accept
Your cancer might grow faster than expected, though this happens rarely. Studies show less than one per cent of men on active surveillance develop cancer spread before treatment catches it. Regular monitoring catches almost all changes early enough for curative treatment. Your consultant watches PSA trends, MRI findings, and biopsy results to identify progression before it becomes dangerous.
You need additional biopsies if tests suggest cancer changes. Transperineal biopsies carry infection risks below one per cent but can cause temporary discomfort and blood in urine or semen. Some men find repeat biopsies stressful even though they’re medically necessary. Your hospital uses the safest biopsy methods to minimise complications.
Your general health might change over time. Developing heart disease, lung problems, or other serious conditions could make surgery or radiotherapy unsafe if you later need treatment. This risk increases with age and applies mainly to men over seventy. Staying physically active and managing other health conditions reduces this likelihood.
Anxiety about living with untreated cancer affects some men. You might worry between appointments or find it hard to stop thinking about the cancer. This psychological burden varies greatly between individuals. Your medical team provides support and you can choose treatment at any point if surveillance becomes too stressful.
Active surveillance and watchful waiting
People often confuse these two approaches because both involve monitoring rather than immediate treatment. Active surveillance prostate cancer programmes and watchful waiting serve different purposes and suit different situations. Your consultant recommends one over the other based on your cancer characteristics, overall health, and treatment goals. The names sound similar but the strategies differ fundamentally in how they monitor you and what happens if your cancer changes.
Key differences between the approaches
Active surveillance targets men who can still receive curative treatment if their cancer progresses. You undergo intensive monitoring with PSA tests every three to six months, annual MRI scans, and possible repeat biopsies. Your consultant aims to catch any cancer growth early whilst you avoid treatment side effects. If tests show progression, you switch to surgery or radiotherapy designed to cure your cancer completely. This approach assumes you’re healthy enough for aggressive treatment later.
Watchful waiting suits men with other serious health conditions that make curative treatment unsafe or inappropriate. You have fewer tests, typically just annual PSA checks at your GP surgery rather than hospital appointments. The goal shifts from cure to symptom management because your overall health means surgery or radiotherapy carries too many risks. If cancer causes problems, you receive hormone therapy to control symptoms rather than eliminate the cancer.
Watchful waiting manages cancer as a chronic condition, whilst active surveillance stays ready to cure it when necessary.
When watchful waiting suits you better
Your consultant suggests watchful waiting if you have significant heart disease, lung conditions, or other illnesses that make you unfit for surgery or radiotherapy. Life expectancy below ten years from other health problems also makes watchful waiting more appropriate. Men diagnosed at advanced ages often benefit from this lighter monitoring approach because aggressive treatment risks outweigh potential benefits.
You might choose watchful waiting if you firmly oppose curative treatment regardless of your health status. Personal preference matters when deciding between these monitoring strategies. Some men accept cancer progression as part of natural ageing and prefer minimal medical intervention.
Questions to ask your urologist
Your consultation with a urologist gives you the chance to understand active surveillance prostate cancer fully before making your decision. Preparing questions in advance ensures you cover all concerns rather than remembering important points after you leave. Your consultant expects questions and allocates time to address them thoroughly. Write down the answers during your appointment so you can review them later when considering your options.
Questions about your specific situation
You need clarity on whether active surveillance truly suits your cancer characteristics. Ask your consultant to explain your Gleason score and what it means for how your cancer behaves. Find out your Cambridge Prognostic Group and whether any features of your cancer make surveillance more or less suitable. Request details about your PSA level and what target range your consultant watches for. Understanding these specifics helps you gauge whether surveillance offers genuine safety or unnecessary risk.
Your overall health affects the decision too. Ask whether you remain fit enough for surgery or radiotherapy if your cancer progresses in five or ten years. Find out what health changes might make curative treatment unsafe later. Your consultant can explain which conditions would force a switch from active surveillance to watchful waiting or immediate treatment.
Understanding your specific cancer characteristics and health status helps you choose between surveillance and immediate treatment with confidence.
Questions about monitoring and next steps
The practical aspects of active surveillance matter as much as the medical rationale. Ask how often you need PSA tests and who books them at your hospital. Find out whether you attend telephone consultations or face-to-face appointments for results. Request details about the MRI scanning schedule and what happens if a scan shows changes. Understanding your time commitment helps you plan work and personal obligations around monitoring.
You need to know what triggers the switch from surveillance to treatment. Ask your consultant which PSA patterns concern them and what level of change prompts additional tests. Find out whether you need repeat biopsies and under what circumstances. Discuss the treatment options available if surveillance ends, including surgery, radiotherapy, and newer techniques. Knowing these details removes uncertainty about what happens if your cancer progresses.
Bringing it all together
Active surveillance prostate cancer offers a proven alternative to immediate treatment for men with localised, low-risk disease. You maintain your quality of life whilst regular monitoring catches any concerning changes early enough for curative treatment. The approach works when your cancer characteristics qualify you, your overall health remains good, and you feel comfortable with regular appointments instead of immediate intervention. Studies confirm that surveillance delivers survival outcomes matching those of surgery or radiotherapy for appropriate candidates.
Your decision depends on understanding your specific situation and priorities. Discuss your Gleason score, PSA trends, and MRI findings with your consultant to determine whether surveillance truly suits your cancer. Consider how you feel about living with monitored cancer versus facing treatment side effects now. Most men on active surveillance never need treatment, but switching to curative options remains possible whenever necessary.
If you’re considering active surveillance or need a second opinion about your diagnosis, book a consultation with Mr Ashwin Sridhar to discuss your individual circumstances and monitoring options in detail.
